Today: 5 June 2026
Unity Software Stock Price Surges 11% After Q1 Revenue Beat, Ad Exit Plan
27 March 2026
2 mins read

Unity Software Stock Price Surges 11% After Q1 Revenue Beat, Ad Exit Plan

NEW YORK, March 27, 2026, 12:12 PM EDT

  • Unity jumped 11.0% to $19.01 late in the morning, after the company raised its preliminary Q1 revenue and profit guidance.
  • Unity plans to wind down the ironSource Ads Network by April 30, and it’s bringing in a financial adviser to help sell off Supersonic. The company says these steps are aimed at accelerating growth and boosting margins.
  • After a rough kickoff to 2026—weak forecasts, new anxiety about AI in game-development tools—the stock bounced.

Unity Software shot up 11.0% to $19.01 as of 11:57 a.m. EDT on Friday, after the videogame software company hiked its preliminary Q1 revenue and profit forecast and announced plans to shed its lower-growth ad and publishing divisions. The stock outperformed in a generally down Wall Street session.

Unity stands out among software stocks in 2026, taking a heavier hit than most. Despite the jump on Friday, shares remain down over 50% year-to-date, Investopedia reports. The rally happened as a sector-wide software ETF slid 3.4%, hit by a wider market drop linked to Middle East turmoil.

Unity bumped its revenue outlook for the March 31 quarter to $505 million to $508 million, topping its earlier range of $480 million to $490 million. Adjusted EBITDA is now seen at $130 million to $135 million, up from the previous $105 million to $110 million. That works out to a margin of roughly 26%, compared with 22% in the earlier view.

Management credited Vector—Unity’s AI tool that connects games with players—for the outperformance, while the Create division, which makes software tools, also topped forecasts. Vector is on track for 15% sequential growth this quarter. “Unity Vector continues to deliver robust growth each quarter, driving results meaningfully above our guidance,” Chief Executive Matt Bromberg said. SEC

Unity plans to wind down the ironSource Ads Network by April 30 and has brought in a financial adviser to explore selling off its Supersonic game-publishing arm. Speaking with CNBC, Bromberg described the decision as “addition by subtraction,” pointing out that Unity is stepping away from “two of our slower growing businesses.” SEC

The company reported that “strategic revenue”—which leaves out ironSource and Supersonic—would have climbed 34% year-over-year to $431 million for the first quarter. For Strategic Grow, its ad and monetization segment minus those units, Unity projects a 48% increase, roughly double the 24% growth rate it’s forecasting for total Grow revenue. SEC

Just back on Feb. 11, Unity sent out a first-quarter revenue outlook that didn’t meet Wall Street’s expectations, knocking the stock down by almost 30% in one day. At the time, Reuters called it a sign of weak demand for Unity’s software.

The selloff didn’t start this week. Back in late January, Unity shares plunged 21% after Alphabet’s Google introduced Project Genie, an AI tool designed to create interactive digital worlds from simple prompts. That same session, Roblox slid more than 12%, and Take-Two lost 10%—investors reacted to fresh worries that the technology might disrupt traditional game development.

Still, the relief rally doesn’t put the matter to rest. Unity’s numbers are unaudited and early, and the company flagged that real outcomes might shift after it wraps up quarter-end checks and makes adjustments. It also cautioned there’s no guarantee that looking into a sale of Supersonic will actually result in a deal.

Stock Market Today

  • Hemogenyx Pharmaceuticals Announces Annual General Meeting and Report Filing
    June 5, 2026, 2:50 AM EDT. Hemogenyx Pharmaceuticals plc (LSE:HEMO) has posted its Annual Report and Accounts for 2025, along with the Notice of its Annual General Meeting (AGM) scheduled for June 30, 2026, at 2:00 pm BST in London. Shareholders will receive the documents by post, which will also be available on the company's investor website. Hemogenyx is a clinical-stage biopharmaceutical company focused on developing treatments for blood and autoimmune diseases. The AGM will address shareholder matters and company progress, providing insights into its ongoing development pipeline. The company is listed on the London Stock Exchange and maintains operational subsidiaries in New York City.

Latest articles

Dow Hits Record, But Wall Street Watches After-Hours Session

Dow Hits Record, But Wall Street Watches After-Hours Session

5 June 2026
Dow soared to a record close, but after-hours jitters hit as Broadcom missed revenue expectations and cut its AI-chip forecast, dragging chip stocks and exposing markets to Friday’s key jobs report, which could sway rates, yields, and tech valuations. Lululemon shares plunged 11% after slashing its profit outlook.
AT&T Stock Drops, Investors Eye SpaceX’s Move

AT&T Stock Drops, Investors Eye SpaceX’s Move

5 June 2026
AT&T shares plunged 3.3% to $22.77 after a Supreme Court loss and an Oppenheimer downgrade citing rising satellite broadband competition, as SpaceX’s $75 billion IPO nears; investors fear AT&T’s fiber-heavy strategy faces new risks, with Oppenheimer warning broadband and mobile growth could be at risk from low Earth orbit rivals.
Marvell rises as chip peers drop, Wall Street eyes index move

Marvell rises as chip peers drop, Wall Street eyes index move

5 June 2026
Marvell jumped 4.9% to $316.43, defying a chip selloff, as traders bet on S&P 500 inclusion and Nvidia-linked AI demand; the stock later slipped to $305.18 after hours, with volume more than double average, as investors await Friday’s S&P announcement and weigh risks of high expectations and index flows.
Guidewire Beats Earnings but Shares Drop on Revenue Number

Guidewire Beats Earnings but Shares Drop on Revenue Number

5 June 2026
Guidewire Software plunged 13.77% after hours to $130.36 as investors fixated on annual recurring revenue guidance that missed Wall Street’s target by a narrow margin, overshadowing strong earnings and revenue beats; the stock’s sharp drop highlights concerns over contract growth pacing despite raised full-year outlooks and robust financials.
Meta and Alphabet Stocks Slide Again After Social Media Addiction Verdicts Raise Liability Fears
Previous Story

Meta and Alphabet Stocks Slide Again After Social Media Addiction Verdicts Raise Liability Fears

UnitedHealth Stock Slides Again as April Earnings Loom, Putting UNH Valuation Under New Scrutiny
Next Story

UnitedHealth Stock Slides Again as April Earnings Loom, Putting UNH Valuation Under New Scrutiny

Go toTop